Creative Edge Nutrition Inc. (FITX) Elects Dr. M. Kerry O'Banion, M.D., Ph.D to Its Board of Directors
May 23 2014 - 7:10AM
Marketwired
Creative Edge Nutrition Inc. (FITX) Elects Dr. M. Kerry O'Banion,
M.D., Ph.D to Its Board of Directors
Highly Accomplished Internationally Recognized Scientist With
Expertise in Neuroscience Further Strengthens Company's Board of
Directors
MADISON HEIGHTS, MI--(Marketwired - May 23, 2014) -
Creative Edge Nutrition, Inc. (OTC Pink: FITX) (PINKSHEETS:
FITX), is pleased to announce that it has elected Dr. M. Kerry
O'Banion, M.D., Ph.D. to its Board of Directors.
Dr. O'Banion is an internationally recognized scientist
specializing in brain inflammation, epilepsy, brain radiation, and
many neurological disorders. A veteran, in neuroscience, Dr.
O'Banion's current research focuses upon pro-inflammatory cytokines
and lipid mediators in traumatic brain injury, Alzheimer's disease,
radiation injury, and psychiatric illnesses.
"We are very fortunate to welcome such a respected industry leader
to serve on our Board," stated Bill Chaaban, President & CEO.
"Dr. Obanion brings both clinical knowledge and business acumen to
CEN Biotech. He has his finger on the pulse of cutting edge
treatment for patients living with neurological conditions and will
undoubtedly be a critical resource for our development and use of
providing ground breaking medicinal cannabis solutions."
Dr. O'Banion is a distinguished leader at the University of
Rochester Medical Center where he directs the NIH-funded Medical
Scientist Training Program as Principal Investigator and serves as
the Director of Medical Neurosciences courses. Dr. O'Banion is
a research leader in individual and program grants with an
outstanding record of NIH funding. His research in
neuroinflammation provided the mechanistic underpinnings that led
to the development of Vioxx and Celebrex, the COX-2 inhibitor pain
relievers, for which he and colleagues were awarded U.S. patents.
As a result he was appointed Assistant Professor of Neurology, and
initiated research into neuroinflammation and its role in
neurodegenerative disease.
Dr. O'Banion received both his M.D. and Ph.D. degrees from the
University of Illinois School of Medicine, Champaign-Urbana, IL,
where he graduated Summa Cum Laude and served as valedictorian for
his graduation class.
About CEN Biotech CEN Biotech, Inc. was established in 2013 as a
partially owned subsidiary of Creative Edge Nutrition (OTC Pink:
FITX) (PINKSHEETS: FITX) for the sole purpose of supplying the
Canadian public with pharmaceutical-grade medical cannabis under
the newly established Marihuana for Medical Purposes Regulations
(MMPR). CEN Biotech Inc. has submitted a comprehensive application
to become a licensed producer (LP) of dried marihuana for medicinal
purposes and has received a ready-to-build approval from Health
Canada. http://www.cenbiotechinc.com
About Creative Edge Nutrition, Inc. Creative Edge Nutrition is a
holding company and a Nutritional Supplement Company focused on
developing innovative, high quality supplements. The company offers
a broad spectrum of capsules, tablets, and powders, as well as
science based products in the principal categories of weight
management, nutrition challenges, energy and fitness. The Company
manufactures under strict GMP guidelines at GMP Certified and/or
FDA registered facilities. http://www.cenergynutrition.com and
https://www.facebook.com/CenergyNutrition
Contact: FOR INVESTOR RELATIONS William Swalm (212) 584-4342
Info@cenergynutrition.com
Creative Edge Nutrition (CE) (USOTC:FITX)
Historical Stock Chart
From Nov 2024 to Dec 2024
Creative Edge Nutrition (CE) (USOTC:FITX)
Historical Stock Chart
From Dec 2023 to Dec 2024
